The Fosun subsidiary is paying the upfront fee, committing up to 1.12 billion yuan ($166 million) in milestones and agreeing ...

Following an examination of clinical evidence and stakeholder input, Canada's Drug Agency (CDA-AMC) has recommended BIMZELX® (bimekizumab injection) for reimbursement with conditions for patients with ...

ATLANTA, May 19, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced Week 16 data from the BE BOLD trial demonstrating superior ACR50 joint outcomes at Week 16 for BIMZELX® ...

UCB (UCBJY) announced on Tuesday that its biologic medicine Bimzelx outperformed AbbVie’s (ABBV) immunology therapy Skyrizi in a head-to-head trial for psoriatic arthritis, an inflammatory condition ...

Two months after UCB revealed the success of Bimzelx in a head-to-head trial against AbbVie’s Skyrizi in patients with psoriatic arthritis (PsA), the Belgian drugmaker has unveiled the detailed ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

After strutting its stuff against blockbusters in three head-to-head psoriasis trials, UCB’s Bimzelx has conquered another powerhouse product—AbbVie’s Skyrizi—in psoriatic arthritis (PsA). A phase 3b ...

President Donald Trump put his personal stamp Thursday night on a new government website, TrumpRx, aimed at helping Americans buy medicines at lower prices. "This is a very big deal," Trump said Feb.

Even when Americans have health insurance, they can have a hard time affording the drugs they’ve been prescribed. About 1 in 5 U.S. adults skip filling a prescription due to its cost at least once a ...

Medicare open enrollment, which lasts until Dec. 7, provides beneficiaries the opportunity to evaluate their health care spending, including prescription costs, for 2026. Certain changes, including a ...

The next leg of a huge share-price rally for Belgium’s UCB SA — driven by the success of its Bimzelx skin disease medicine — hinges on key results for a rival drug. The Belgian biotech’s stock could ...